SINGAPORE: The Novavax/Nuvaxovid XBB1.5 COVID-19 vaccination will no longer be available under the federal vaccination programme from Jan 1 second year.
The national immunization program’s updated COVID-19 punch was released in May of this year.
The manufacturer of the vaccine is no longer providing it, according to the Ministry of Health ( MOH) in a press release on Tuesday ( Dec 3 ), and Singapore’s current stocks are set to expire on December 31.
According to MOH, those who qualify must submit their application by December 31 to obtain the vaccine’s current development.
According to the Health Ministry, those taking the vaccine as an extra dose should wait at least a year and within five months of the last prescription, according to the Health Ministry.
Novavax is currently requesting regulatory approval for its updated COVID-19 vaccination preparation, according to MOH.
When the business has effectively obtained regulation approval and supplies are available in Singapore, according to MOH, additional updates will be provided.
Sinovac’s COVID-19 immunizations had , ceased to be offered under the program at the end of September this year.
MOH said then that , the Health Sciences Authority ( HSA ) did not receive any application for the Sinovac vaccine to be fully registered,
The updated JN. 1 rna vaccines- PfizerBioNTech/Comirnaty and Moderna/Spikevax- will continue to be accessible under the federal vaccination program, it said.
Both were approved by HSA, MOH said in October.
Through the HealthHub ordering program, users can make an visit at a Healthier SG GP center or a facility.
Mobile vaccination team offering COVID-19 vaccinations will continue to be deployed across Singapore, MOH said.
” We encourage people, particularly those aged 60 years and above or clinically vulnerable, to be updated with their immunization based on the prevailing advice”, MOH added.